The single most dangerous threat to Hershey’s long-term growth trajectory and margin expansion is the unprecedented, structural crisis in the global cocoa supply chain, coupled with the emerging macroeconomic threat posed by the rapid adoption of GLP-1 weight-loss medications that fundamentally alter consumer caloric consumption patterns. In fiscal year 2024, while Hershey achieved a 2.1% increase in total net sales to $11.36 billion, the company did so against the backdrop of cocoa futures prices surging past $12,000 per metric ton in early 2025, a staggering 400% increase from the historical average of $2,500 to $3,000 per ton. This price spike was not driven by temporary market speculation, but by a catastrophic, structural failure in the West African cocoa crop, which accounts for over 60% of global supply. The combination of the El Niño weather pattern, which brought excessive rainfall and humidity to Ivory Coast and Ghana, and the rampant spread of the swollen shoot virus and black pod disease, has decimated cocoa yields, leading to a severe supply deficit that is projected to persist for at least the next three to five years as new cocoa trees take up to seven years to reach full maturity. Hershey’s commodity hedging program, while highly sophisticated and effective at locking in prices up to 36 months in advance, only delays the inevitable; as the company’s forward book rolls off and it is forced to purchase cocoa at current spot prices, the cost of goods sold for its core chocolate portfolio will increase dramatically. The company faces a brutal strategic dilemma: it can continue to pass these costs onto consumers through aggressive price increases, but doing so will inevitably test the limits of consumer price elasticity, potentially triggering a severe volume decline as shoppers trade down to private label alternatives or abandon the category entirely. Conversely, if Hershey absorbs the cost increases to protect its market share, its gross margins will be severely compressed, potentially erasing the operating profit gains achieved over the past five years and forcing the company to cut vital marketing and innovation investments. Beyond the cocoa crisis, Hershey faces a persistent, structural risk regarding the long-term impact of GLP-1 receptor agonist drugs, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The rapid adoption of these medications, which are prescribed for weight management and type 2 diabetes, has fundamentally altered the eating habits of millions of Americans. Clinical trials and real-world consumer data indicate that GLP-1 users experience a significant reduction in appetite, a decreased desire for highly palatable, hyper-processed foods, and a shift toward higher-protein, lower-sugar nutritional profiles. Hershey’s core chocolate portfolio, which is inherently high in sugar and fat, is directly exposed to this dietary shift. If the penetration of GLP-1 drugs continues to accelerate, reaching 10% to 15% of the U.S. population over the next decade, the total addressable market for traditional confectionery could structurally contract, forcing Hershey to rely entirely on its salty snack and better-for-you portfolio to drive top-line growth. While the company has made significant strides in diversifying its portfolio through the acquisitions of ONE Brands, SkinnyPop, and Dot’s, these categories are fiercely competitive and lack the same dominant market share and pricing power that Hershey enjoys in the chocolate aisle. Furthermore, the company operates in a highly consolidated retail environment where a handful of massive retailers, including Walmart, Amazon, Kroger, and Costco, wield immense negotiating power. These retailers are increasingly demanding lower wholesale prices, higher trade promotion funding, and exclusive product innovations to drive foot traffic and loyalty in a deflationary consumer spending environment. Hershey’s DSD network, while a significant competitive advantage, is also a massive fixed-cost structure; the company must maintain its fleet of over 4,000 vehicles and its army of direct sales representatives regardless of sales volume, meaning that any significant decline in unit cases will result in severe operating deleverage and margin compression. Additionally, Hershey faces intense scrutiny from global regulators and non-governmental organizations regarding the prevalence of child labor and deforestation in its West African cocoa supply chain. Despite the company’s implementation of the Hershey Cocoa For Good sustainability program and its investment in traceability technologies, the complex, fragmented nature of the West African cocoa supply chain, which relies on over two million smallholder farms, makes it nearly impossible to guarantee that every bean is entirely free from child labor or linked to illegal deforestation. The European Union’s implementation of the Deforestation Regulation (EUDR), which bans the import of commodities linked to forest clearance, adds a massive layer of compliance cost and operational complexity to Hershey’s international supply chain. If the company fails to meet these stringent regulatory requirements, it could face massive fines, product seizures, and severe reputational damage that would alienate the growing demographic of environmentally conscious consumers. Finally, the company must navigate the intense competitive pressure from its global rivals, particularly Mars Wrigley and Mondelez International, both of which possess vastly greater financial resources and are aggressively investing in premiumization, seasonal innovation, and international expansion to capture market share in the mature North American market. The combination of record input cost inflation, the potential structural decline in chocolate consumption driven by GLP-1 drugs, intense retail negotiating power, and stringent sustainability regulations creates a hostile operating environment that will test the resilience of Hershey’s management team and its ability to execute its strategic pivot toward a diversified snacking portfolio.